Cargando…

Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis

SIMPLE SUMMARY: Currently, the only curative therapy in myelofibrosis is allogeneic hematopoietic stem cell transplantation. Donor lymphocyte infusion and second stem cell transplantation are the two main treatment options for myelofibrosis patients who relapse after the first transplantation. The o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atagunduz, Isik Kaygusuz, Klyuchnikov, Evgeny, Wolschke, Christine, Janson, Dietlinde, Heidenreich, Silke, Christopeit, Maximilian, Ayuk, Francis, Kröger, Nicolaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690833/ https://www.ncbi.nlm.nih.gov/pubmed/33114179 http://dx.doi.org/10.3390/cancers12113098

Ejemplares similares

Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation
por: Gagelmann, Nico, et al.
Publicado: (2023)

TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
por: Gagelmann, Nico, et al.
Publicado: (2021)

Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis
por: Mannina, Daniele, et al.
Publicado: (2022)

Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection
por: Christopeit, Maximilian, et al.
Publicado: (2021)

Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML
por: Niederwieser, Christian, et al.
Publicado: (2021)

Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
por: Modemann, Franziska, et al.
Publicado: (2020)

Correction: Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
por: Modemann, Franziska, et al.
Publicado: (2021)

Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation
por: Massoud, Radwan, et al.
Publicado: (2021)

Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients
por: Gagelmann, Nico, et al.
Publicado: (2023)

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse
por: Srivastava, Barnali, et al.
Publicado: (2023)

Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation
por: Massoud, Radwan, et al.
Publicado: (2022)

Real-life ruxolitinib experience in intermediate-risk myelofibrosis
por: Arikan, Fatma, et al.
Publicado: (2021)

Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment
por: Marquard, Franziska, et al.
Publicado: (2023)

Endothelial complications after allogeneic stem cell transplantation in patients with pretransplant resolved COVID-19
por: Niederwieser, Christian, et al.
Publicado: (2022)

Stem cell transplantation in myelofibrosis
por: Kröger, Nicolaus
Publicado: (2018)

Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
por: Gagelmann, Nico, et al.
Publicado: (2022)

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients
por: Klyuchnikov, Evgeny, et al.
Publicado: (2011)

P1024: IMPACT OF TP53 IN MYELOFIBROSIS UNDERGOING STEM CELL TRANSPLANTATION
por: Gagelmann, N., et al.
Publicado: (2022)

Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy
por: Berger, Susanna Carolina, et al.
Publicado: (2022)

Is Treosulfan-Based Conditioning Attractive as a Reduced-Intensity Conditioning Regimen in Korea?
por: Kim, Se Hyung, et al.
Publicado: (2023)

Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection
por: Heidenreich, Silke, et al.
Publicado: (2017)

Stammzelltransplantation bei Multipler Sklerose - wo stehen wir?
por: Heesen, Christoph, et al.
Publicado: (2022)

Viral Dynamics of SARS-CoV-2 in Critically Ill Allogeneic Hematopoietic Stem Cell Transplant Recipients and Immunocompetent Patients with COVID-19
por: Roedl, Kevin, et al.
Publicado: (2021)

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
por: Gagelmann, Nico, et al.
Publicado: (2021)

DNA alkylation and interstrand cross-linking by treosulfan
por: Hartley, J A, et al.
Publicado: (1999)

Treosulfan-based conditioning for inborn errors of immunity
por: Slatter, Mary A., et al.
Publicado: (2021)

Treosulfan-Based Conditioning Regimen in Sibling and Alternative Donor Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease
por: Marzollo, Antonio, et al.
Publicado: (2017)

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
por: Saraceni, Francesco, et al.
Publicado: (2019)

Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Levofloxacin for the treatment of severe refractory BK virus-associated hemorrhagic cystitis in hematopoietic stem cell transplantation recipients: A report of three cases
por: TOPTAS, TAYFUR, et al.
Publicado: (2014)

Treosulfan induces distinctive gonadal toxicity compared with busulfan
por: Levi, Mattan, et al.
Publicado: (2018)

In Vitro Study of the Enzymatic and Nonenzymatic Conjugation of Treosulfan with Glutathione
por: Romański, Michał, et al.
Publicado: (2019)

Molecular Diagnostics, Targeted Therapy, and the Indication for Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
por: Oyekunle, Anthony, et al.
Publicado: (2011)

High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis
por: Gagelmann, Nico, et al.
Publicado: (2022)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
por: McLornan, Donal P., et al.
Publicado: (2019)

Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019)

Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle
por: Malek, Ehsan, et al.
Publicado: (2017)

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019)

Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma
por: Gillich, Cédric, et al.
Publicado: (2023)

Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial
por: Lazzari, Lorenzo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9fg2ug0ubgd7gt5lgi2ka4i6de